Supplementary Materials

Supplementary Material for:

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

Cameron J. Turtle,* Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian, Xueyan Chen, Lorinda Soma, Brent Wood, Daniel Li, Shelly Heimfeld, Stanley R. Riddell, David G. Maloney

*Corresponding author. Email: cturtle{at}fhcrc.org

Published 7 September 2016, Sci. Transl. Med. 8, 355ra116 (2016)
DOI: 10.1126/scitranslmed.aaf8621

This PDF file includes:

  • Fig. S1. Plan of CD19 CAR-T cell manufacturing.
  • Fig. S2. CAR-T cell product characterization.
  • Fig. S3. Anti-CAR transgene product immune response.
  • Fig. S4. Tumor regression after a second CAR-T cell infusion in patients who received Cy/Flu lymphodepletion.
  • Fig. S5. Delayed normalization of imaging after CD19 CAR-T cell infusion.
  • Table S1. Variable CD4+/CD8+ T cell ratio in blood of NHL patients.
  • Table S2. Summary of anti-CAR transgene product immune responses.
  • Table S3. CRS and neurotoxicity.
  • Table S4. Multivariate analyses.
  • Table S5. Simultaneous and sequential testing of cytokines to predict toxicity.
  • Table S6. P values for Figs. 4 (B and E) and 5 (A and B).
  • Reference (39)

[Download PDF]